新生儿黄疸120例临床分析

目的探讨口服思密达治疗新生儿黄疸的临床疗效。方法将我科2005年1月～2008年12月收治的120例新生儿黄疸的患儿随机分为治疗组和对照组各60例。治疗组在酶诱导剂治疗的基础上加用思密达粉口服，3g×1／3包（1g），用20mL温水稀释均匀口服，每日3次。对照组在酶诱导剂治疗的基础上加用蓝光照射治疗，每天照射8～12h。两组均经皮黄疸仪测量正常（〈12mg／L）后抽血查胆红素。结果两组治疗前血清胆红素比较无显著性差异（P〉0．05）。每组治疗前后比较差异显著（P〈0．01），两组治疗后血清胆红素值比较有差异（P〈0．05）。两组黄疸高峰日龄比较，治疗组出现时间比对照组提前（P〈0．05）。结论思密达治疗新生儿黄疸可以缩短黄疸持续时间，快速降低血清胆红素，副作用少，临床应用安全有效。

Neonatal Jaundice:A Clinical Analysis of 120 Cases

Objective To observe the clinical efficacy of oral Smecta in the treatment of neonatal jaundice. Methods We divided 120 cases of neonatal jaundice in our hospital from Jan 2005 to Dec 2008 randomly into two groups;treatment group and control group with 60 cases for each group. The treatment group was given oral Smecta（3g× 1/3 package（lg）,diluted with 20mL warm water, 3 times a day） on the basis of the enzyme inducer treatment. The control group was given Blu-ray irradiation （a daily irradiation from 8 to 12h） on the basis of the enzyme inducer treatment. Jaundice was measured with transcutaneous jaundice meter and after jaundice was normal（〈12mg/L）, the blood bilirubin was examined. Results The two groups showed no significant difference in the serum bilirubin before treatment（P〉0.05）, each group showed a significant difference in the serum bilirubin before and after treatment（P〈 0,01）,and there was a significant difference in the serum bilirubin in the two groups after treatment（P〈0.05）. Jaundice peak day age of the treatment group appeared earlier than that of the control group（P〈0.05）. Conclusion Smecta for the treatment of neonatal jaundice can shorten the duration of jaundice and rapidly reduce serum bilirubin,and it is safe and effective,with less side effects.